Raymond James Trust Has Upped At&T (T) Position; Dicerna Pharmaceuticals, Inc. (DRNA) Had 4 Bullish Analysts

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Raymond James Trust increased At&T Inc (T) stake by 3.22% reported in 2018Q1 SEC filing. Raymond James Trust acquired 14,752 shares as At&T Inc (T)’s stock declined 13.21%. The Raymond James Trust holds 472,586 shares with $16.85 million value, up from 457,834 last quarter. At&T Inc now has $207.63 billion valuation. The stock increased 1.29% or $0.43 during the last trading session, reaching $33.81. About 42.56M shares traded or 48.37% up from the average. AT&T Inc. (NYSE:T) has declined 14.96% since June 8, 2017 and is downtrending. It has underperformed by 27.53% the S&P500. Some Historical T News: ; 12/04/2018 – QATAR BOND TRANCHES INCLUDE $3 BLN MATURING IN 2028, PRICED AT T PLUS 170 BASIS POINTS; 06/04/2018 – AT&T Bond Exchange Offer Makes Small Dent in TWX Debt Costs: BI; 08/05/2018 – AT&T confirms it paid Trump lawyer Michael Cohen for ‘insights’ on administration; 11/05/2018 – CNBC Wires: EXCLUSIVE-AT&T HEAD OF EXTERNAL AND LEGISLATIVE AFFAIRS BOB QUINN IS RETIRING -MEMO; 26/04/2018 – Time Warner Doesn’t Need AT&T Deal to Succeed — Heard on the Street; 06/03/2018 – AT&T Sees FY18 Adj EPS Growth in Low Single Digits, Outlines Capital Plans; 11/05/2018 – White House says that the AT&T-Cohen issue proves President Trump is “draining the swamp.”; 16/03/2018 – U.S. IS SAID TO MULL NAFTA TELECOM PROPOSAL TO END AT&T IMPASSE; 29/03/2018 – The Information: AT&T Develops Networking Switch, in Blow to Cisco; 15/03/2018 – Daily Mail: AT&T/Time Warner merger trial to be delayed two days

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. On Monday, August 10 the stock rating was maintained by Stifel Nicolaus with “Buy”. H.C. Wainwright downgraded the shares of DRNA in report on Friday, March 23 to “Neutral” rating. The rating was initiated by H.C. Wainwright with “Buy” on Monday, December 12. The stock has “Neutral” rating by Chardan Capital Markets on Monday, August 15. The rating was maintained by Chardan Capital Markets with “Hold” on Friday, August 11. As per Tuesday, July 18, the company rating was maintained by Cowen & Co. As per Thursday, June 30, the company rating was maintained by Chardan Capital Markets. As per Wednesday, August 16, the company rating was maintained by Cowen & Co. As per Wednesday, April 11, the company rating was initiated by Cowen & Co. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Thursday, June 30. Stifel Nicolaus has “Buy” rating and $13 target. See Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) latest ratings:

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

Investors sentiment increased to 0.92 in 2018 Q1. Its up 0.01, from 0.91 in 2017Q4. It is positive, as 76 investors sold T shares while 695 reduced holdings. 122 funds opened positions while 585 raised stakes. 3.08 billion shares or 0.35% less from 3.09 billion shares in 2017Q4 were reported. Northstar Gru owns 13,373 shares. First Citizens Commercial Bank Co holds 0.95% or 196,119 shares. Homrich Berg holds 1.72% of its portfolio in AT&T Inc. (NYSE:T) for 695,296 shares. Reilly Fincl Advsr Lc, a California-based fund reported 44,562 shares. Bryn Mawr Tru stated it has 0.43% of its portfolio in AT&T Inc. (NYSE:T). Zevin Asset Ltd Liability Corp accumulated 2.66% or 287,206 shares. Family Firm Inc has 0.1% invested in AT&T Inc. (NYSE:T). Van Hulzen Asset Mgmt Limited Com, California-based fund reported 23,689 shares. Moreover, Shelton Capital Mgmt has 0.3% invested in AT&T Inc. (NYSE:T) for 127,658 shares. Amg Tru Comml Bank has 0.09% invested in AT&T Inc. (NYSE:T). Meyer Handelman Com stated it has 0.41% in AT&T Inc. (NYSE:T). Whittier Tru Of Nevada Incorporated accumulated 222,993 shares. Gam Hldgs Ag invested 0.17% in AT&T Inc. (NYSE:T). Field And Main Fincl Bank has 0.87% invested in AT&T Inc. (NYSE:T). Moreover, Agf Invests America has 0.46% invested in AT&T Inc. (NYSE:T).

More notable recent AT&T Inc. (NYSE:T) news were published by: Seekingalpha.com which released: “Retirement Strategies: Time For AT&T?” on June 07, 2018, also Seekingalpha.com with their article: “AT&T: The Clock Is Ticking” published on May 30, 2018, Fool.com published: “Is Sprint Corp. (S) a Buy?” on June 07, 2018. More interesting news about AT&T Inc. (NYSE:T) were released by: Seekingalpha.com and their article: “AT&T dips on analyst downgrade citing cord-cutting concerns” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “AT&T Is A Buy – Cramer’s Lightning Round (6/6/18)” with publication date: June 07, 2018.

Raymond James Trust decreased Microsoft Corp (NASDAQ:MSFT) stake by 7,758 shares to 373,496 valued at $34.09M in 2018Q1. It also reduced 3M Co (NYSE:MMM) stake by 4,736 shares and now owns 57,094 shares. Nvidia (NASDAQ:NVDA) was reduced too.

Among 33 analysts covering AT&T Inc. (NYSE:T), 12 have Buy rating, 1 Sell and 20 Hold. Therefore 36% are positive. AT&T Inc. has $54 highest and $35 lowest target. $41.10’s average target is 21.56% above currents $33.81 stock price. AT&T Inc. had 84 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was downgraded by UBS to “Neutral” on Wednesday, September 28. On Tuesday, June 28 the stock rating was maintained by Deutsche Bank with “Buy”. Macquarie Research maintained AT&T Inc. (NYSE:T) on Tuesday, July 25 with “Buy” rating. The stock of AT&T Inc. (NYSE:T) has “Buy” rating given on Tuesday, November 21 by Robert W. Baird. Bank of America downgraded the shares of T in report on Thursday, July 13 to “Neutral” rating. The company was maintained on Friday, July 7 by RBC Capital Markets. The stock has “Buy” rating by Argus Research on Tuesday, April 11. Wells Fargo maintained AT&T Inc. (NYSE:T) rating on Friday, February 23. Wells Fargo has “Buy” rating and $48.0 target. The firm has “Buy” rating by DA Davidson given on Thursday, February 4. The firm has “Perform” rating by Oppenheimer given on Tuesday, November 8.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $736.33 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Seekingalpha.com which released: “Dicerna Pharmaceuticals’ (DRNA) CEO Douglas Fambrough on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. Also Nasdaq.com published the news titled: “Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR …” on May 18, 2018. Investingnews.com‘s news article titled: “Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial” with publication date: May 30, 2018 was also an interesting one.

Since December 18, 2017, it had 1 buying transaction, and 4 selling transactions for $1.57 million activity. 9,669 shares were sold by Brown Bob D, worth $145,035 on Wednesday, May 9. $13,455 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was sold by Weissman James B. Bain Capital Life Sciences Investors – LLC bought $2.00M worth of stock or 285,000 shares.

The stock decreased 3.06% or $0.44 during the last trading session, reaching $13.94. About 203,006 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 8, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: ; 20/04/2018 – Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals; 20/04/2018 – ALNYLAM REACHES SETTLEMENT PACT WITH DICERNA PHARMACEUTICALS; 08/03/2018 Dicerna Pharmaceuticals 4Q Loss/Shr 90c; 14/05/2018 – Dicerna Pharmaceuticals Believes It Has Sufficient Cash Through 2019, Assuming No New Fundin; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 20/04/2018 – DICERNA PHARMACEUTICALS – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending

Investors sentiment decreased to 2.44 in 2018 Q1. Its down 0.56, from 3 in 2017Q4. It dived, as 3 investors sold Dicerna Pharmaceuticals, Inc. shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. Emory University has invested 1.68% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers Tru has 151,571 shares for 0.06% of their portfolio. Millennium Management Limited Liability holds 407,530 shares or 0.01% of its portfolio. The Connecticut-based Cubist Systematic Strategies Ltd Llc has invested 0.01% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 683 Limited Co invested in 0.11% or 125,000 shares. Jane Street Limited Company stated it has 14,262 shares. Acadian Asset Management Limited accumulated 23,566 shares. 47,286 are held by Eam Investors. Panagora Asset Mgmt Inc owns 7,533 shares for 0% of their portfolio. Virtu Ltd Company holds 0.01% or 14,416 shares. California Employees Retirement Sys holds 0% or 41,000 shares. Bogle Inv Limited Partnership De holds 18,798 shares or 0.01% of its portfolio. Manchester Cap Mgmt Ltd Liability Corp owns 18,857 shares. Birchview Ltd Partnership owns 45,000 shares or 0.28% of their US portfolio. Vanguard Group reported 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart